| Nome del prodotto | Noopept |
| Other Names | GVS-111; N-Phenylacetyl-L-prolylglycine ethyl ester |
| Numero CAS | 157115-85-0 |
| Formula molecolare | C₁₇H₂₂N₂O₄ |
| Peso molecolare | 334.37 g/mol |
| Aspetto | Polvere cristallina di colore da bianco a bianco sporco |
| Analisi (HPLC) | ≥ 99,01 TP3T |
| Punto di fusione | 95–98°C |
| Perdita per essiccazione | ≤ 0,51 TP3T |
| Residuo di combustione | ≤ 0,11 TP3T |
| Metalli pesanti | ≤ 10 ppm |
Hai bisogno di aiuto? Contatta il nostro team
Noopept (developmental code GVS-111) is a dipeptide nootropic compound developed in Russia in the 1990s as a novel cognitive enhancer with neuroprotective properties. Structurally, it is a cycloprolyl-glycine derivative that shares some pharmacological similarities with racetams (particularly piracetam), but with significantly higher potency—estimated to be approximately 1,000 times more potent than piracetam.
Key : Unlike most nootropics that require weeks to show effects, Noopept has demonstrated rapid onset in research models. It exhibits both cognitive-enhancing e neuroprotective properties, including protection against oxidative stress, excitotoxicity, and ischemia-reperfusion injury. Noopept also increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) levels in the hippocampus.
Noopept exerts its effects through multiple pathways, distinguishing it from classic racetams:
| Pathway | Meccanismo | Research Finding |
|---|---|---|
| BDNF/NGF upregulation | Increases brain-derived neurotrophic factor and nerve growth factor in hippocampus | Supports synaptic plasticity, neurogenesis |
| AMPA/kainate receptor modulation | Positive allosteric modulation (similar to racetams) | Enhances glutamatergic transmission |
| Neuroprotection | Reduces oxidative stress, inhibits lipid peroxidation, protects against excitotoxicity | Preclinical models of ischemia, traumatic brain injury |
| Cholinergic system | May enhance acetylcholine release (indirect) | Memory and learning support |
| Antinfiammatorio | Reduces neuroinflammation (preclinical) | Neuroprotection |
Noopept has been shown to protect against neurodegeneration in animal models of Alzheimer’s disease, Parkinson’s disease, and cerebral ischemia. It reduces amyloid-β toxicity and may have disease-modifying potential (preclinical only).
LyvBio S.r.l. is a GMP-certified supplier of high-purity Noopept (GVS-111) for research and development applications.
Capacità di fornitura:
Analisi (HPLC): ≥99,01 TP3T
Modulo: Polvere cristallina
Capacità mensile: 20+ kg
Quantità all'ingrosso: 1g – 10kg
Tempi di consegna: 3–5 giorni (campioni), 10–15 giorni (grandi quantità)
Documentazione: COA, MSDS, HNMR , HPLC chromatogram, stability data
Garanzia di qualità:
Purezza determinata mediante HPLC con rilevamento UV
Solventi residui analizzati (conforme alla norma USP )
Metalli pesanti analizzati (ICP-MS)
Structural confirmation (NMR upon request)
📧 Per informazioni: info@lyvbio.com
| Parametro | Specifiche | Metodo di prova |
|---|---|---|
| Analisi (HPLC) | ≥ 99,01 TP3T | HPLC-UV (210 nm) |
| Aspetto | Polvere cristallina di colore da bianco a bianco sporco | Visivo |
| Identificazione | HPLC retention time, NMR (upon request) | HPLC / NMR |
| Punto di fusione | 95–98°C | USP |
| Perdita per essiccazione | ≤ 0,51 TP3T | USP |
| Residuo di combustione | ≤ 0,11 TP3T | USP |
| Metalli pesanti | Pb ≤ 10 ppm; As ≤ 2 ppm; Cd ≤ 1 ppm; Hg ≤ 0,1 ppm | ICP-MS |
| Sostanze correlate | Impurità singola ≤ 0,51 TP3T; Totale ≤ 1,01 TP3T | HPLC-UV |
| Solventi residui | Scopri la norma USP | GC |
| Dimensione delle particelle | Da 95% a 80 mesh | Analisi granulometrica |
Q: Is Noopept the same as Piracetam?
A: No. Noopept is a dipeptide derivative with different chemical structure, significantly higher potency (~1,000x), and distinct mechanisms (including BDNF/NGF upregulation). It is not a racetam, though it shares some pharmacological similarities.
Q: Is Noopept FDA-approved?
A: No. Noopept is not FDA-approved for medical use in the United States. It is available as a research chemical for laboratory use only. It has been used as a prescription medication in Russia.
Q: What is the difference between Noopept and other nootropics?
A: Noopept is unique in its ability to upregulate BDNF and NGF in the hippocampus—a property not shared by classic racetams. It is also significantly more potent (microgram vs. milligram dosing).
Q: What is the primary active metabolite of Noopept?
A: Cycloprolylglycine (CPG). Noopept is rapidly metabolized to CPG, which is believed to contribute significantly to its pharmacological effects.
Q: Does Noopept have neuroprotective properties?
A: Yes. Preclinical studies have demonstrated neuroprotective effects in models of stroke, traumatic brain injury, excitotoxicity, and neurodegeneration (Alzheimer’s, Parkinson’s models).
Q: What is the effective dose range in animal studies?
A: Published studies report cognitive-enhancing and neuroprotective effects at 0.1–1 mg/kg (oral) in rodents—approximately 1,000 times more potent than piracetam.
Q: Are there human clinical trials for Noopept?
A: Limited human studies have been conducted in Russia, where Noopept is approved as a prescription nootropic.
Per informazioni: info@lyvbio.com
English English 
Russian
French
Korean
German
Polish
Japanese
Spanish
Italian
Vietnamese